Advertisement

Topics

Nordic Nanovector: Safety Review Committee supports dose escalation with Betalutin in Lymrit 37-01 trial pending safety data from cohort receiving higher pre-dosing

02:29 EDT 23 Sep 2016 | FinanzNachrichten

Dose-escalation of Betalutin® accompanied by increase in lilotomab pre-dosing could further improve efficacy while maintaining a favourable safety profile Nordic Nanovector ASA (OSE:NANO)(OSE:NANO...

Original Article: Nordic Nanovector: Safety Review Committee supports dose escalation with Betalutin in Lymrit 37-01 trial pending safety data from cohort receiving higher pre-dosing

NEXT ARTICLE

More From BioPortfolio on "Nordic Nanovector: Safety Review Committee supports dose escalation with Betalutin in Lymrit 37-01 trial pending safety data from cohort receiving higher pre-dosing"

Quick Search
Advertisement